Survodutide is under clinical development by Boehringer Ingelheim International and currently in Phase III for Overweight.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with ...

StudyFinds' Dr. Faith Colemans explains why shopping for weight loss drugs online may save you money but endanger your health ...

The year had a lot to offer, from advanced therapies aimed at Lp(a), GLP-1, and other targets, to support for simpler ...

The following is a summary of “Association of Perioperative Glucagon-like Peptide-1 Receptor Agonist Use and Postoperative ...

Insurers said one major driver of higher premiums is the growing popularity of a relatively new class of injectable drugs to ...

The US Food and Drug Administration has approved the first generic referencing Victoza (liraglutide; Hikma Pharmaceuticals), ...

RTW Biotech added that last Monday, Corxel said it acquired worldwide rights to an oral small molecule glucagon-like peptide-1 receptor agonist known as CX11 from Suzhou, China-based Vincentage Pharma ...

Ozempic and Wegovy are two popular injectable medications for weight loss and diabetes. But what’s the difference?

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 ...

GLP-1, or Glucagon-like peptide-1, medications, similar to Ozemppic and Wegovy, are becoming more accessible, and while the ...